Clinical Efficacy and Safety of CMOD Regimen as the First Treatment for Aged New-diagnosed Patients with Peripheral T-cell Lymphoma / 中国实验血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To investigate clinical efficacy and safety of CMOD regimen as the first treatment for the aged new-diagnosed patients with peripheral T-cell lymphoma.</p><p><b>METHODS</b>Seventy-six patients diagnosed as peripheral T cell lymphoma according to chemotherapy were divided into the 2 group A and B groups. The patients in A group received CMOD regimen (38 cases) and the patients in B group received CHOP regiment (38 cases). The clinical efficacy, PFS (progression-free survival), OS and the adverse reactions in the 2 groups were compared.</p><p><b>RESULTS</b>The total effeciency rate was not statistically different between CMOD(64.52%) and CHOP groups (58.06%) (P>0.05). The adverse reactions in 2 groups were as follows myelosuppression, mucositis, gastrointestinal reactions, fever, liver dysfunction, neurotoxicity, and alopecia etc. The incidence of alopecia and the grade III and IV of neutropenia in the CMOD group (34.21%, 13.16%) were statistically significantly lower than those in the CHOP group (84.21%, 34.21%) (P<0.05). The progression-free survival and 1-year overall survival of observation group (10.98±2.23 months, 14.43±2.48 months) were significantly higher than those in the CHOP group(8.31±2.62 months, 10.93±2.07 months) (P<0.05).</p><p><b>CONCLUSION</b>The clinical efficacy of CMOD regimen has been confirmed to be equivalent with CHOP regimen for the aged new-diagnosed patients with peripheral T-cell lymphoma. This regimen can prolong the progression-free survival and overall survival to some extent and reduce the incidence of hair loss and neutropenia, which may be applied to the clinical practice.</p>